ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $44.00

ArriVent BioPharma (NASDAQ:AVBP) had its target price upped by HC Wainwright from $42.00 to $44.00 in a research note issued to investors on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

AVBP has been the subject of a number of other reports. Zacks Research upgraded ArriVent BioPharma from a “strong sell” rating to a “hold” rating in a research report on Friday, December 5th. Citigroup lowered their price target on ArriVent BioPharma from $33.00 to $31.00 and set a “buy” rating on the stock in a research report on Tuesday, November 11th. Truist Financial began coverage on ArriVent BioPharma in a research note on Tuesday, November 25th. They issued a “buy” rating and a $43.00 price objective on the stock. Cantor Fitzgerald initiated coverage on ArriVent BioPharma in a report on Monday, December 22nd. They issued an “overweight” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ArriVent BioPharma in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $41.11.

ArriVent BioPharma Trading Down 7.2%

AVBP stock opened at $23.43 on Friday. The firm’s 50-day moving average is $22.20 and its two-hundred day moving average is $20.94. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of -5.31 and a beta of 0.98. ArriVent BioPharma has a 52 week low of $15.47 and a 52 week high of $27.22.

ArriVent BioPharma (NASDAQ:AVBP) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.09. On average, equities research analysts predict that ArriVent BioPharma will post -2.74 earnings per share for the current year.

Institutional Trading of ArriVent BioPharma

A number of large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC bought a new position in shares of ArriVent BioPharma in the fourth quarter valued at $227,000. Invesco Ltd. lifted its position in shares of ArriVent BioPharma by 12.5% during the 4th quarter. Invesco Ltd. now owns 16,892 shares of the company’s stock valued at $340,000 after acquiring an additional 1,876 shares during the last quarter. XTX Topco Ltd bought a new stake in shares of ArriVent BioPharma during the 4th quarter worth $528,000. Virtus Investment Advisers LLC boosted its stake in shares of ArriVent BioPharma by 126.2% during the 4th quarter. Virtus Investment Advisers LLC now owns 10,894 shares of the company’s stock worth $219,000 after acquiring an additional 6,078 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of ArriVent BioPharma by 0.7% in the 4th quarter. Wellington Management Group LLP now owns 82,278 shares of the company’s stock worth $1,655,000 after acquiring an additional 532 shares during the last quarter. 9.48% of the stock is currently owned by institutional investors.

Key Stories Impacting ArriVent BioPharma

Here are the key news stories impacting ArriVent BioPharma this week:

• Positive Sentiment: Oppenheimer reaffirmed an “outperform” rating and raised its price target to $50 (from $44), a large upside vs. the current price. Oppenheimer boosts PT to $50
• Positive Sentiment: Citigroup raised its price target from $31 to $33 and kept a “buy” rating, signaling more analyst conviction. Citigroup raises PT to $33
• Positive Sentiment: HC Wainwright raised its target from $42 to $44 and maintained a “buy” rating—another analyst upgrade supporting upside. HC Wainwright raises PT to $44
• Positive Sentiment: Unusually large options activity: traders bought about 1,832 call contracts (≈321% above typical call volume), indicative of short-term bullish positioning.
• Positive Sentiment: Quarterly EPS beat: AVBP reported loss-per-share of ($0.78) vs. consensus ($0.87), a small beat that reduces near-term execution risk. Quarterly results press release
• Neutral Sentiment: Company released full-year 2025 financial results and highlighted progress; no headline surprises were reported in the summary notice. Full-year 2025 results
• Neutral Sentiment: Consensus brokerage coverage remains constructive (“Moderate Buy”), reflecting overall analyst support but not an immediate catalyst. Consensus recommendation coverage
• Neutral Sentiment: Reported short-interest entries show inconsistent/zero values (data artifact), so there’s no clear evidence of rising short pressure based on the published figures.
• Negative Sentiment: Despite the bullish signals above, AVBP is trading down on heavy volume — likely profit-taking, option-driven hedging flows, or broader market weakness outweighing analyst upgrades in the near term. Investors should watch intraday volume, near-term option activity, and any sector-wide moves for further direction.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002.